Were Richard F. Pops’ NBIX share sales under a Rule 10b5-1 plan?

Yes. The disposition of 15,000 Neurocrine shares was executed by a broker under a Rule 10b5-1 trading plan. The footnotes state this plan was adopted and became effective on February 13, 2026, before the May 15, 2026 transactions.

Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised 15,000 Non-Qualified Stock Options at a strike price of $47.89 per share and on the same day sold 15,000 common shares in open-market transactions. The weighted average sale price was $157.6507 per share, with individual trades ranging from $155.51 to $158.68. These sales were executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026. Following the transactions, Pops directly holds 34,480 shares of Neurocrine common stock. The options exercised were granted on May 20, 2016 and are scheduled to expire on May 20, 2026.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares ($2,364,761)

Net Sell 3 txns

Insider POPS RICHARD F

Role null

Sold 15,000 shs ($2.36M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option	15,000	$0.00	--
Exercise	Common Stock	15,000	$47.89	$718K
Sale	Common Stock	15,000	$157.6507	$2.36M

Holdings After Transaction: Non-Qualified Stock Option — 0 shares (Direct, null); Common Stock — 49,480 shares (Direct, null)

Footnotes (1)

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on February 13, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.51 to $158.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options will expire ten years from the date of grant on May 20, 2026.

Key Figures

Shares sold: 15,000 shares Weighted average sale price: $157.6507/share Options exercised: 15,000 options +4 more

7 metrics

Shares sold 15,000 shares Open-market sale of common stock on May 15, 2026

Weighted average sale price $157.6507/share Sales in range $155.51–$158.68 on May 15, 2026

Options exercised 15,000 options Non-Qualified Stock Options converted into common stock

Option strike price $47.89/share Exercise price for Non-Qualified Stock Options granted May 20, 2016

Shares held after transactions 34,480 shares Direct common stock holdings following May 15, 2026 trades

Rule 10b5-1 plan adoption date February 13, 2026 Plan governing broker-executed sales

Option expiration date May 20, 2026 Non-Qualified Stock Options expire 10 years after grant

Key Terms

Rule 10b5-1 trading plan, Non-Qualified Stock Option, weighted average sales price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Non-Qualified Stock Option financial

"security_title": "Non-Qualified Stock Option""

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

weighted average sales price financial

"Represents a weighted average sales price per share. These shares were sold in multiple transactions"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 05:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POPS RICHARD F

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		M		15,000	A	$47.89	49,480	D
Common Stock	05/15/2026		S⁽¹⁾		15,000	D	$157.6507⁽²⁾	34,480	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option	$47.89	05/15/2026		M			15,000	⁽³⁾	05/20/2026	Common Stock	15,000	$0	0	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on February 13, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.51 to $158.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options will expire ten years from the date of grant on May 20, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did NBIX director Richard F. Pops report?

Richard F. Pops exercised 15,000 Non-Qualified Stock Options at $47.89 per share and sold 15,000 Neurocrine common shares. The sales occurred in open-market transactions on May 15, 2026 at a weighted average price of $157.6507.

At what prices did Richard F. Pops sell NBIX shares?

Pops sold 15,000 Neurocrine common shares at a weighted average price of $157.6507 per share. The trades were executed in multiple transactions, with prices ranging from $155.51 to $158.68, as disclosed in the filing footnotes.

How many NBIX shares does Richard F. Pops hold after these trades?

After the reported transactions, Richard F. Pops directly holds 34,480 shares of Neurocrine common stock. This post-transaction holding reflects the exercise of 15,000 options and the sale of 15,000 shares on May 15, 2026, as shown in the Form 4.

What options did Richard F. Pops exercise in this NBIX Form 4?

He exercised 15,000 Non-Qualified Stock Options convertible into 15,000 Neurocrine common shares at a strike price of $47.89 per share. The options were granted on May 20, 2016 and are scheduled to expire on May 20, 2026, according to the footnotes.

How were the vesting and expiration terms of Pops’ NBIX options described?

The Non-Qualified Stock Options were granted on May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. The filing notes these options will expire ten years from grant, on May 20, 2026, if not exercised earlier.